Microbiome Testing

BA Sciences provides comprehensive identity, purity, and potency testing services for microbiome-based drug products, supporting product characterization and pharmaceutical development. Our analytical testing capabilities help drug developers evaluate critical quality attributes and advance microbiome therapeutics toward clinical trials, including treatments targeting diseases and conditions associated with imbalances in the gut microbiome.

BA Sciences has extensive experience supporting microbiome drug development and analytical testing programs, including products manufactured using spore fraction and defined microbial manufacturing processes. Our experienced microbiologists work closely with drug developers to establish comprehensive testing strategies, including microbiome environmental monitoring program qualification, microbial characterization, and molecular assay design, tailored to each product’s development stage and testing requirements.

To support microbiome drug product characterization and quality control, BA Sciences utilizes advanced analytical instrumentation, including MALDI-TOF mass spectrometry for microbial identification, a Roche LightCycler® system for quantitative polymerase chain reaction (qPCR) testing, and multiple anaerobic workstations with ambient and incubated environments. These capabilities allow our team to develop customized microbiological testing and monitoring programs that support microbiome therapeutic development, manufacturing process monitoring, and product quality throughout the drug development lifecycle.

Contact Us

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
Company Address*

Why is Microbiome Microbial Characterization Necessary?

An imbalance in the gut microbiome, commonly referred to as gut dysbiosis, has been associated with various gastrointestinal conditions, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and recurrent gastrointestinal infections. As research continues to advance, pharmaceutical and biotechnology companies are developing microbiome-based therapeutics and live biotherapeutic products (LBPs) designed to restore or support a healthy gut microbiome and address conditions associated with microbial imbalance.

BA Sciences supports microbiome drug development through specialized microbiological testing, microbial identification, and characterization services. Our analytical capabilities help pharmaceutical developers evaluate microbial composition, identity, purity, and other critical quality attributes throughout research, development, and manufacturing. These testing services provide valuable data to support product characterization, quality control, and the development of appropriate testing strategies for microbiome-based drug products.

One of our specialized capabilities includes spore fraction analysis, which focuses on the isolation, identification, and characterization of spore-forming microorganisms within microbial samples. This testing can help evaluate the presence and quantity of spore-forming bacteria in donor-derived stool samples, microbiome drug substances, and finished live biotherapeutic products. By providing reliable microbial characterization and analytical testing, BA Sciences helps drug developers establish appropriate quality controls, monitor product consistency, and generate data to support the development of safe, effective microbiome therapeutics.

Microbiome Drug Product Characterization and Testing Services

  • Microbial Identification and Characterization: Colony morphology, Gram staining, and applicable USP <61> and <62>  testing.
  • colony and gram stain morphology
  • Physicochemical and Impurity Testing: Appearance, pH, residual moisture, disintegration, elemental impurities, and organic impurities.
  • Microbial Titer Testing: Quantification of viable microorganisms in drug substance and drug product samples.
  • Microbial Strain Identification: Confirmation of defined microbial strains using molecular and proteomic methods and reference libraries.
  • Environmental Monitoring: Microbiological monitoring of pharmaceutical manufacturing cleanrooms and controlled environments.
  • Disinfectant Efficacy Testing: Studies informed by USP <1072> and applicable AOAC methods.

Why Work with BA Sciences?

BA Sciences combines advanced analytical testing technologies, experienced scientists, and modern laboratory facilities to support pharmaceutical and biotechnology drug development programs. Our team provides personalized microbiome testing and characterization services tailored to each project’s analytical and regulatory requirements.

Every client is assigned a dedicated project manager who serves as an extension of their team, providing clear communication, technical coordination, and ongoing support throughout the project. From initial testing strategies to final analytical results, BA Sciences works closely with clients to deliver reliable data and efficient project execution.

Ready to discuss your microbiome drug development or analytical testing needs? Contact BA Sciences to learn how our team can support your next project.

Ready to get started? Tell us about your upcoming project

Get an Accurate, Timely Quote
Tell Us About Your Project